The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,778.00
Bid: 1,774.00
Ask: 1,774.50
Change: -10.50 (-0.59%)
Spread: 0.50 (0.028%)
Open: 1,796.00
High: 1,808.50
Low: 1,772.50
Prev. Close: 1,788.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 2-West Africa Ebola outbreak could infect 20,000 people, WHO says

Thu, 28th Aug 2014 17:19

* Number of cases possibly 2-4 times higher than reported

* 12,000 local staff, 750 international experts needed

* Nigeria reports spread to main African oil hub

* Air service suspension threatens aid operation - WHO (Adds details, quotes)

By Stephanie Nebehay and Tim Cocks

GENEVA/LAGOS, Aug 28 (Reuters) - The Ebola epidemic in WestAfrica could infect over 20,000 people and spread to morecountries, the U.N. health agency said on Thursday, warning thatan international effort costing almost half a billion dollars isneeded to overcome the outbreak.

The World Health Organisation (WHO) announced a $490 millionstrategic plan to contain the epidemic over the next ninemonths, saying it was based on a projection that the virus couldspread to 10 further countries beyond the four now affected -Guinea, Liberia, Sierra Leone and Nigeria.

With the IMF warning about the economic effects of theoutbreak, Nigeria reported that a doctor indirectly linked tothe Liberian-American who brought the disease to the country haddied of Ebola in Port Harcourt, Africa's largest energy hub.

In Britain, drugmaker GlaxoSmithKline said anexperimental Ebola vaccine is being fast-tracked into humanstudies and it plans to produce up to 10,000 doses for emergencydeployment if the results are good.

So far 3,069 cases have been reported in the outbreak butthe WHO said the actual number could already be two to fourtimes higher. "This is not a West African issue or an Africanissue. This is a global health security issue," WHO's AssistantDirector-General Dr Bruce Aylward told reporters in Geneva.

With a fatality rate of 52 percent, the death toll stood at1,552 as of Aug. 26. That is nearly as high as the total fromall recorded outbreaks since Ebola was discovered in what is nowDemocratic Republic of Congo in 1976.

The figures do not include deaths from a separate Ebolaoutbreak announced at the weekend in Congo, which has beenidentified as a different strain of the virus.

Aylward said tackling the epidemic would need thousands oflocal staff and 750 international experts. "It is a bigoperation. We are talking (about) well over 12,000 peopleoperating over multiple geographies and high-risk circumstances.It is an expensive operation," he said.

The operation marks a major raising of the response by theWHO, which had been accused by some aid agencies of reacting tooslowly to the outbreak.

Medical charity Medecins sans Frontieres (MSF) welcomed theWHO plan but said the important thing was now to act upon it.

"Huge questions remain about who will implement the elementsin the plan," said MSF operations director Brice de le Vingne."None of the organisations in the most-affected countries ...currently have the right set-up to respond on the scalenecessary to make a serious impact."

EXPERIMENTAL DRUGS

Early this month, the WHO classified the Ebola outbreak asan international health emergency. Concerns that the diseasecould spread beyond West Africa have led to the use of drugsstill under development for the treatment of a handful of cases.

Two American health workers, who contracted Ebola whiletreating patients in Liberia, received an experimental therapycalled ZMapp, a cocktail of antibodies made by tiny Californiabiotech Mapp Biopharmaceutical. They recovered and were releasedfrom hospital last week.

The virus has already killed an unprecedented number ofhealth workers and is still being spread in a many places, theWHO said. About 40 percent of the cases have occurred within thepast 21 days, its statistics showed.

Previous Ebola outbreaks have mainly occurred in isolatedareas of Central Africa. However the current epidemic has spreadto three West African capitals and Lagos, Africa's biggest city.The WHO said special attention would need to be given tostopping transmission in capital cities and major ports.

Authorities in Nigeria announced the doctor's death in PortHarcourt, the main oil industry terminal of Africa's largestcrude exporter. The doctor had treated a patient who evadedquarantine after coming into contact with Patrick Sawyer - aU.S. citizen who died in Lagos after flying in from Liberia lastmonth.

Health Ministry spokesman Dan Nwomeh wrote in his Twitterfeed that 70 people were now under surveillance in PortHarcourt, which is home to foreigners working for internationaloil companies.

A spokesman for leading operator Royal Dutch Shell said in London that the firm was "liaising with healthauthorities on the steps being taken to contain the disease".

Oil traders in Europe said insurance premiums for Nigeriancargoes had gone up slightly, but otherwise business wascontinuing as normal.

Analysts urged caution. "While major disruption to oilproduction appears unlikely, any further spread of Ebola ... islikely to cause serious operational challenges," said RoddyBarclay of the Control Risks consultancy.

According to new figures released on Thursday, Nigeria hasrecorded 17 cases, including six deaths, from Ebola, sinceSawyer collapsed upon arrival at Lagos airport in late July.

While Nigeria has yet to suffer any major economicdisruption, the International Monetary Fund said the smaller,poorer nations at the heart of the epidemic were being badlyhurt. "The Ebola outbreak is having an acute macroeconomic andsocial impact on three already fragile countries in WestAfrica," IMF spokesman Gerry Rice told reporters in Washington.

Rice said the IMF was assessing the impact and any extrafinancing needs with Guinea, Liberia and Sierra Leone.

AID EFFORT CHOKED OFF

The Lagos case contributed to the decision by a number ofairlines to halt services to Ebola-affected countries. AirFrance said on Wednesday it had suspended flights toSierra Leone on the advice of the Frenchgovernment.

Aylward said it was vital to restore commercial airlineroutes to the region to help transport aid workers and supplies,but in the meantime the WHO plan includes an "air bridge" to beoperated by the U.N.'s World Food Programme.

"We assume current airline limitations will stop within thenext couple of weeks. This is absolutely vital," he said. "Rightnow the aid effort risks being choked off."

West African health ministers meeting in Ghana on Thursdayechoed the WHO's concerns and called for the reopening ofborders and an end to flight bans. (Additional reporting by Kwasi Kpodo in Accra, Ben Hirschlerand Julia Payne in London, Anna Yukhananov in Washington andSharon Begley in New York; Writing by Joe Bavier; Editing byDaniel Flynn and David Stamp)

More News
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.